From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease.


O'Hallahan, J; Lennon, D; Oster, P; Lane, R; Reid, S; Mulholland, K; Stewart, J; Penney, L; Percival, T; Martin, D; (2005) From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine, 23 (17-18). pp. 2197-201. ISSN 0264-410X DOI: 10.1016/j.vaccine.2005.01.061

Full text not available from this repository.

Abstract

New Zealand has been affected by an epidemic of group B meningococcal disease dominated by a strain defined as, B:4:P1.7b,4. Over 5550 cases and 222 deaths have been reported since 1991 in a population of 4 million people.Meningococcal disease cases notified on EpiServ database operated by Institute of Environmental Science and Research Limited through to 30 September 2004. Through the collaborative efforts of a government agency, vaccine company, university and laboratory institute, clinical trials of the Chiron produced outer membrane vesicle (OMV) strain-specific MeNZB vaccine were run in rapid succession. The delivery of MeNZB will be New Zealand's largest immunisation programme with three doses given at 6-week intervals to over 1 million people aged 6 weeks-19 year olds inclusive. Planning, co-ordinating and delivering the immunisation programme is a challenging project for the New Zealand Health Sector.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Vaccine Centre
PubMed ID: 15755594
Web of Science ID: 227898700032
URI: http://researchonline.lshtm.ac.uk/id/eprint/13088

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
288Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item